These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30219366)

  • 1. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.
    Carrell RK; Stanton RA; Ethier SP; LaRue AC; Soloff AC
    Vaccine; 2018 Oct; 36(42):6262-6269. PubMed ID: 30219366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
    Shi FF; Gunn GR; Snyder LA; Goletz TJ
    Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
    Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
    Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Th1 cytokine responses fail to effectively control Chlamydia lung infection in ICOS ligand knockout mice.
    Kadkhoda K; Wang S; Joyee AG; Fan Y; Yang J; Yang X
    J Immunol; 2010 Apr; 184(7):3780-8. PubMed ID: 20190137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
    Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
    J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
    Koido S; Enomoto Y; Apostolopoulos V; Gong J
    Anticancer Res; 2014 Aug; 34(8):3917-24. PubMed ID: 25075013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
    Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
    Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAM10-Mediated ICOS Ligand Shedding on B Cells Is Necessary for Proper T Cell ICOS Regulation and T Follicular Helper Responses.
    Lownik JC; Luker AJ; Damle SR; Cooley LF; El Sayed R; Hutloff A; Pitzalis C; Martin RK; El Shikh MEM; Conrad DH
    J Immunol; 2017 Oct; 199(7):2305-2315. PubMed ID: 28814605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role and plasticity of Th1 and Th17 responses in immunity to
    Ferraro A; Buonocore SM; Auquier P; Nicolas I; Wallemacq H; Boutriau D; van der Most RG
    Hum Vaccin Immunother; 2019; 15(12):2980-2992. PubMed ID: 31149870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducible co-stimulatory molecule ligand is protective during the induction and effector phases of crescentic glomerulonephritis.
    Odobasic D; Kitching AR; Semple TJ; Holdsworth SR
    J Am Soc Nephrol; 2006 Apr; 17(4):1044-53. PubMed ID: 16540559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dynamic alteration of CD154/CD40 and its effects on Th1/Th2 polarization in inducible co-stimulator ligand knockout mice infected with Schistosoma japonicum].
    Wang Y; Xia CM
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 47(6):898-904. PubMed ID: 26679647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.
    Dobrzanski MJ; Rewers-Felkins KA; Quinlin IS; Samad KA; Phillips CA; Robinson W; Dobrzanski DJ; Wright SE
    Clin Immunol; 2009 Dec; 133(3):333-52. PubMed ID: 19762283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterium tuberculosis RpfE promotes simultaneous Th1- and Th17-type T-cell immunity via TLR4-dependent maturation of dendritic cells.
    Choi HG; Kim WS; Back YW; Kim H; Kwon KW; Kim JS; Shin SJ; Kim HJ
    Eur J Immunol; 2015 Jul; 45(7):1957-71. PubMed ID: 25907170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The membrane-bound mucin Muc1 regulates T helper 17-cell responses and colitis in mice.
    Nishida A; Lau CW; Zhang M; Andoh A; Shi HN; Mizoguchi E; Mizoguchi A
    Gastroenterology; 2012 Apr; 142(4):865-874.e2. PubMed ID: 22202458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
    Barratt-Boyes SM; Vlad A; Finn OJ
    Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells.
    Vocanson M; Rozieres A; Hennino A; Poyet G; Gaillard V; Renaudineau S; Achachi A; Benetiere J; Kaiserlian D; Dubois B; Nicolas JF
    J Allergy Clin Immunol; 2010 Aug; 126(2):280-9, 289.e1-7. PubMed ID: 20624644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-17 suppresses the therapeutic activity of cancer vaccines through the inhibition of CD8
    Dadaglio G; Fayolle C; Oberkampf M; Tang A; Rudilla F; Couillin I; Torheim EA; Rosenbaum P; Leclerc C
    Oncoimmunology; 2020 May; 9(1):1758606. PubMed ID: 32923117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher susceptibility to experimental autoimmune encephalomyelitis in Muc1-deficient mice is associated with increased Th1/Th17 responses.
    Yen JH; Xu S; Park YS; Ganea D; Kim KC
    Brain Behav Immun; 2013 Mar; 29():70-81. PubMed ID: 23261777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.